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Background: We aimed to identify differences in disparities among patients with a cancer in which
screening is widely recommended (colorectal cancer [CRC]) and one in which it is not (esophageal
cancer).
Methods: A retrospective analysis was performed using 2004e2015 data from the National Cancer
Database. Multivariable generalized logistic regression was used to identify potential differences in the
effect of disparities in stage at diagnosis.
Results: A total of 96,524 esophageal cancer patients and 361,187 CRC patients were included. Black
patients, longer travel distances, and lower educational attainment were only associated with increased
odds of stage IV CRC. While both Medicaid and uninsured patients were more likely to be diagnosed with
stage IV esophageal and CRC, the effect was larger among CRC patients. From 2004 to 2015, the rates of
stage IV esophageal cancer decreased from 42.0% to 38.2%, while the rates of stage IV CRC increased from
36.9% to 40.8% (p < 0.0001).
Conclusions: Disparities are more pronounced in CRC, compared to esophageal cancer. Equity in access to
screening and cancer care should be prioritized.Introduction
Cancer is a global public health problem and is the second
leading cause of death in the United States (US).1 Despite remark-
able medical advances in early diagnosis and treatment of several
cancer types, racial and socioeconomic inequalities persist in can-
cer survival.2,3 Unequal access to care and inadequate health care
utilization are the main determinants of these disparities.4,5
Colorectal cancer (CRC) is the third most common cancer in both
men andwomen in the US, with approximately 135,430 individuals
newly diagnosed and 50,260 deaths from the disease in 2017.6
Esophageal cancer is less frequent in the US, with approximately
16,940 new cases and 15,690 deaths in 2017.7 However, the inci-
dence of esophageal adenocarcinoma is expected to increase sub-
stantially in the US because of the rising prevalence of obesity and
gastroesophageal reflux disease.8,9 Both CRC and esophageal cancer
have poor prognoses when diagnosed at stage IV with distanta at Chapel Hill 101, Manning
lottmann).metastases (5-year survival rates of 13.9% and 4.6%,
respectively).7,10
The purpose of this analysis was to assess whether the effects of
disparities on stage of diagnosis differ across patients with a cancer
in which screening is recommended (CRC), compared to one with
no such recommendation (esophageal cancer). We hypothesized
that disparities would be amplified in cancers inwhich screening is
available and widely recommended.
Methods
A cohort of patients was identified using the National Cancer
Database (NCDB) between January 1, 2004 and December 31, 2015.
The NCDB is a national hospital-based cancer registry program
implemented by the Commission on Cancer of the American Col-
lege of Surgeons and the American Cancer Society. The database
includes over 1500 hospitals and obtains close to 70% of incident
cancer cases in the US.
Adult patients (18 years old) with a diagnosis of esophageal
cancer or CRC were eligible for inclusion. Stage of cancer at diag-
nosis was ascertained using the TNM staging system of the Amer-
ican Joint Commission of Cancer (AJCC). Patients with missing age
or missing TNM staging data were excluded from the analysis.
Statistical analysis
Patient demographics and cancer characteristics for patients
with both esophageal cancer and CRC were reported using
descriptive statistics. Yearly rates in stage at diagnosis, stratified by
cancer type, were assessed using Poisson regression.
Multivariable generalized logistic regression was used to assess
whether the impact of race, residential income, travel distance
(categorized into quartiles), primary insurance, and education on
the odds of having a cancer diagnosed at each stage relative to stage
I (outcome reference category) differed between patients with
esophageal cancer and CRC. Both educational attainment, defined
as the percentage of adults in a given patient’s ZIP code who did not
graduate from high school and split into quartiles, and residential
income, defined as the median household income in the ZIP code of
a patient’s residence and split into quartiles, were derived from the
linked 2012 American Community Survey. Travel distance, reported
as the distance between centroid of the patient’s zip code and the
address of their primary cancer care hospital, was also split into
quartiles for analysis. Interaction terms between cancer type
(esophageal cancer vs. CRC) and each disparity and likelihood ratio
tests were used to determine whether the effect on stage at diag-
nosis was significantly different between the two cancers. The
model was also adjusted for patient age (modeled as a restricted
cubic spline), sex, Charlson-Deyo comorbidity score, and year of
diagnosis.
Finally, we performed a sensitivity analysis restricting the
cohort to ages in which screening for CRC is mostly recommended,
including CRC patients 50 years old.
A p-value <0.05 was considered significant for all the statistical
methods.
All analyses were performed using SAS software version 9.4
(SAS Inc., Cary, NC).
Results
A total of 96,524 esophageal cancer patients and 361,187 CRC
patients were included. Stage IV at diagnosis was present in 39% of
the esophageal cancer patients, and in 35% of the CRC patients.
Patient characteristics, stratified by stage at diagnosis, for esopha-
geal and CRC cancer are described in Tables 1 and 2, respectively.
Between 2004 and 2015, the number of esophageal cancers diag-
nosed at stage I increased from 10.2% to 13.1%, while the number
diagnosed at stage IV decreased from 42.0% to 38.2%, p < 0.0001
(Fig. 1). For CRC, the number of cancers diagnosed at stage I
remained relatively constant from 26.3% to 26.7%, but the number
diagnosed at stage IV increased from 36.9% to 40.8%, p < 0.0001
(Fig. 2).
Race
Among patients with esophageal cancer, black patients were
more likely to be diagnosed with stage III cancer (OR 1.25, 95% CI
1.15, 1.37), compared to stage I, and other race patients were more
likely to be diagnosed with both stage II (1.20, 95% CI 1.02, 1.42) and
stage III (OR 1.44, 95% CI 1,22, 1.69); however, no difference in the
odds of stage IV diagnoses were seen (OR 1.04, 95% CI 0.96, 1.13, and
OR 1.11, 95% CI 0.95, 1.30, respectively) (Table 3).
In patients with CRC, both black and other race patients were
more likely to be diagnosed with stage III (OR 1.06, 95% CI 1.03, 1.10
and OR 1.14, 95% CI 1.08,1.20) and stage IV (OR 1.34, 95% CI 1.30,1.37
and OR 1.04, 1.00, 1.10) disease, although the association between
other race and stage IV disease was minimal. The effect of race onstage at diagnosis was significantly different between esophageal
cancer and CRC patients, p < 0.0001.
Primary insurance
When compared to patients with private insurance, Medicaid
and uninsured patients had higher odds of both stage III (OR 1.20,
95% CI 1.08, 1.33 and OR 1.53, 95% CI 1.31, 1.78) and stage IV
esophageal cancer (OR 1.34, 95% CI 1.21, 1.47 and OR 1.99, 95% CI
1.72, 2.31, respectively). Patients with Medicaid and those unin-
sured were also more likely to be diagnosed with stage II (OR 1.44,
95% CI 1.37, 1.51 and OR 2.05, 95% CI 1.92, 2.17), stage III (OR 1.44,
95% CI 1.37, 1.52 and OR 1.90, 95% CI 1.78, 2.02), and stage IV (OR
1.94, 95% CI 1.86, 2.02 and OR 1.22, 95% CI 2.21, 2.46) CRC, although
the magnitude of the effects were more pronounced (p < 0.0001).
Interestingly, patients with Medicare were significantly less likely
to be diagnosed with stage II, stage III, and stage IV esophageal
disease, whereas Medicare patients with CRC were slightly more
likely to be diagnosed with more advanced stages (Table 3).
Travel distance
Among patients diagnosed with esophageal cancer, travel dis-
tance had an inverse impact on the odds of being diagnosed with
advanced disease. Patients who were 18 miles from their cancer
center were significantly less likely to be diagnosed with stage II
(OR 0.78, 95% CI 0.73, 0.83), stage III (OR 0.79, 95% CI 0.74, 0.84), and
stage IV (OR 0.50, 95% CI 0.47, 0.53) disease; moreover, across all
increased travel distances, a decreased odds of stage IV diagnosis
was observed (Table 3).
Travel distance had minimal impact on stage at diagnosis after
adjustment in patients with CRC; however, patients who were 18
miles from their cancer center were significantly more likely to be
diagnosed with stage IV cancer (OR 1.20, 95% CI 1.17, 1.23). The ef-
fect of travel distance on stage at diagnosis was also significantly
different across cancer type, p < 0.0001.
Residential income
Median residential income also hadminimal impact on the odds
of advanced disease diagnoses across both esophageal cancer and
CRC, and the effect of income on stage at diagnosis was relatively
consistent across CRC and esophageal cancer (Table 3).
Education
Education level of a patient’s zip code had nomeaningful impact
on the stage of diagnosis in esophageal cancer (Table 3). However,
that was not the case for CRC. Patients living in areas where 7% of
adults did not complete high school were fairly consistently more
likely to be diagnosed with stage II, stage III, and stage IV disease.
Unsurprisingly, the effect of education on stage at diagnosis was
also differential across cancer type (p ¼ 0.002).
Disparities in CRC patients  50 years old
When restricting the cohort to ages in which screening for CRC
is mostly recommended, we found similar results. Black patients
weremore likely to be diagnosed with stage IV cancer. Compared to
patients with private insurance, Medicaid, Medicare, and uninsured
patients had higher odds of being diagnosed with stage IV cancer.
Similarly, patients living in areas where 7% of adults did not
complete high school were more likely to be diagnosed with stage
IV disease (Appendix Table).
Table 1
Distribution of patient characteristics among patients diagnosed with esophageal cancer, stratified by stage at diagnosis, n ¼ 96,524.
Stage I
N ¼ 12,637 (13%)
Stage II
N ¼ 23,965 (25%)
Stage III
N ¼ 22,620 (23%)
Stage IV
N ¼ 37,302 (39%)
Age in years, mean (SD) 68.9 (11.4) 67.5 (11.2) 65.6 (11.1) 64.8 (11.7)
Male, n (%) 9701 (76.8) 18,562 (77.5) 17,714 (78.3) 30,540 (81.9)
Race, n (%)
White 11,264 (90.7) 21,193 (89.3) 19,465 (86.9) 32,328 (87.5)
Black 929 (7.5) 1992 (8.4) 2308 (10.3) 3767 (10.2)
Other 227 (1.8) 549 (2.3) 616 (2.8) 872 (2.4)
Charlson comorbidity score
0 8905 (70.5) 17,216 (71.8) 16,844 (74.5) 27,547 (73.9)
1 2675 (21.2) 4971 (20.7) 4455 (19.7) 7213 (19.3)
2 731 (5.8) 1300 (5.4) 965 (4.3) 1802 (4.8)
3 326 (2.6) 478 (2.0) 356 (1.6) 749 (2.0)
Primary insurance, n (%)
Private 3729 (30.7) 7667 (33.5) 7857 (36.7) 13,205 (36.8)
Medicaid 587 (4.8) 1366 (6.0) 1644 (7.7) 3168 (8.8)
Medicare 7592 (62.6) 13,303 (58.1) 11,116 (51.9) 17,709 (49.4)
Uninsured 226 (1.9) 545 (2.4) 805 (3.8) 1788 (5.0)
Travel distance
<4 miles 2275 (18.3) 4906 (20.8) 4459 (20.1) 9093 (24.9)
4e7.9 miles 2100 (16.9) 4407 (18.7) 4055 (18.3) 7628 (20.9)
8e17.9 miles 2669 (21.4) 5385 (22.8) 5125 (23.1) 8845 (24.2)
18 miles 5404 (43.4) 8898 (37.7) 8537 (38.5) 10,998 (30.1)
Residential incomea
<$38,000 2118 (17.0) 4151 (17.6) 4104 (18.5) 6971 (19.1)
$38,000 - $47,999 3057 (24.6) 5737 (24.3) 5436 (24.5) 9155 (25.1)
$48,000 - $62,999 3443 (27.7) 6461 (27.4) 5856 (26.4) 9757 (26.7)
$63,000 3823 (30.7) 7222 (30.6) 6766 (30.5) 10,671 (29.2)
Educationb, n (%)
<7% 2978 (23.9) 5666 (24.0) 5097 (23.0) 8151 (22.3)
7e12.9% 4359 (35.0) 8212 (34.8) 7468 (33.7) 12,387 (33.9)
13%e20.9% 3293 (26.5) 6159 (26.1) 5876 (26.5) 9849 (26.9)
21% 1817 (14.6) 3551 (15.1) 3735 (16.8) 6183 (16.9)
Abbreviations: SD, standard deviation.
a Median residential household income estimated using the 2012 American Community Survey.
b Proportion of adults in patient’s ZIP code who did not complete high school, measured in the 2012 American Community Survey.Discussion
In this study, we sought to assess whether the impact of dis-
parities on the stage at diagnosis among patients with a cancer that
has established screening guidelines, recommendations, and
mandates (CRC) differed from one in which screening guidelines
are not clearly established nor recommended (esophageal cancer).
We found that disparities primarily existed for CRC only, and were
more pronounced when compared to patients with esophageal
cancer.
Previous studies have documented disparities in CRC survival by
race and ethnicity.11e14 Arshad et al.13 found that among black pa-
tients, 40.9% presented with stage IV CRC, as compared to 25% of
non-Hispanic whites. Ellis and colleagues14 previously stated that
stage at diagnosis had the greatest influence on overall racial/ethnic
survival disparities. We also found that black patients were
significantly more likely to have advanced CRC. Interestingly, we
did not find racial disparities in esophageal cancer. This observed
difference may be attributable to the variations in the carcinogenic
mechanisms and genetic factors among black adults with CRC.15
However, inadequate access to screening and earlier detection is
also likely amajor contributing factor. Some studies have reported a
greater overall distrust of the healthcare system amongst black
patients, which reduces the likelihood of seeking medical care.16,17
Thus, increasing medical trust and healthcare utilization by black
patients may help decrease the evident racial disparities in CRC.
We also found that patients living in areas with higher median
residential incomes were slightly less likely to be diagnosed with
advanced stages of both esophageal cancer and CRC. Lower income
has also associated with increased risk of stage IV cancer in previ-
ous studies.18,19 Travel burden appears to play an important role indisparities for screening-mandated cancers. In our study, longer
distances between residence of patient and hospital were associ-
ated with increased odds of stage IV diagnosis only in CRC. Rural
populations have been shown to have lower rates of localized stage
cancer and higher rates of distant stage cancer among cancers with
preventive opportunities.20,21 Specifically, for CRC, Anderson et al.21
showed that rural vs. urban residence, travel time to the nearest
colonoscopy provider, and spatial accessibility of providers were all
significantly associated with adherence to screening guidelines. We
also found that geographic proximity to cancer screening providers
is a key factor contributing to cancer disparities in CRC. Interest-
ingly, we also found that increased travel distances were inversely
associated with stage of diagnosis among esophageal patients.
Additional research is needed to assess this association and identify
the potential causes.
Insurance status is a strong predictor of disparities in access and
quality of cancer care.22 Uninsured individuals have shown higher
rates of advanced disease and shorter overall survival in several
cancer types.23e25 In our cohort, uninsured patients were also more
likely to be diagnosed with stage IV in both esophageal cancer and
CRC, although the magnitude of the effect was greater in CRC. Insur-
ance coverage has been one of the major achievements of the
Affordable Care Act (ACA). The number of uninsured Americans
declined from49million in2010 to 29million in2015 (uninsured rate
dropped from16.0% in2010 to 9.1% in2015). This is the largest decline
in the uninsured rate since the implementation of Medicare and
Medicaid in 1965.26 The increase in number of insured patients was
mostlydue toMedicaidexpansion. In fact, theuninsuredratedropped
36.3% in states that implemented the ACA’s Medicaid expansion,
compared with 23.9% in states without expansion.27 Increasing the
number of persons with health insurance is commendable and can
Table 2
Distribution of patient characteristics among patients diagnosed with colorectal cancer, stratified by stage at diagnosis, n ¼ 361,187.
Stage I
N ¼ 101,786 (28%)
Stage II
N ¼ 72,879 (20%)
Stage III
N ¼ 59,131 (16%)
Stage IV
N ¼ 127,391 (35%)
Age in years, mean (SD) 68.2 (13.3) 69.3 (13.6) 66.4 (14.2) 65.6 (14.1)
Male, n (%) 50,609 (49.7) 35,506 (48.7) 28,993 (49.0) 65,288 (51.3)
Race, n (%)
White 86,121 (85.4) 61,712 (85.4) 48,746 (83.1) 101,607 (80.5)
Black 11,126 (11.0) 7927 (11.0) 7406 (12.6) 19,714 (15.6)
Other 3582 (3.6) 2660 (3.7) 2500 (4.3) 4913 (3.9)
Charlson comorbidity score
0 70,503 (69.3) 50,139 (68.8) 42,455 (71.8) 93,456 (73.4)
1 22,199 (21.8) 16,454 (22.6) 12,261 (20.7) 24,582 (19.3)
2 6373 (6.3) 4519 (6.2) 3188 (5.4) 6321 (5.0)
3 2711 (2.7) 1767 (2.4) 1227 (2.1) 3032 (2.4)
Primary insurance, n (%)
Private 35,452 (35.6) 22,015 (31.0) 21,187 (36.9) 44,701 (36.1)
Medicaid 3807 (3.8) 3428 (4.8) 3368 (5.9) 9763 (7.0)
Medicare 58,177 (58.5) 42,973 (60.5) 30,439 (53.0) 62,951 (50.8)
Uninsured 2058 (2.1) 2633 (3.7) 2409 (4.2) 6462 (5.2)
Travel distance
<4 miles 28,163 (27.9) 20,973 (29.0) 16,340 (27.9) 33,512 (26.7)
4e7.9 miles 23,883 (23.6) 16,949 (23.5) 13,516 (23.1) 27,894 (22.3)
8e17.9 miles 25,450 (25.2) 17,498 (24.2) 14,562 (24.9) 29,937 (23.9)
18 miles 23,577 (23.3) 16,824 (23.3) 14,078 (24.1) 34,037 (27.2)
Residential income a
< $38,000 16,840 (16.7) 13,271 (18.4) 10,843 (18.6) 25,122 (20.0)
$38,000 - $47,999 23,971 (23.7) 17,345 (24.0) 13,669 (23.4) 29,809 (23.8)
$48,000 - $62,999 27,339 (27.1) 19,202 (26.6) 15,483 (26.5) 32,570 (26.0)
$63,000 32,856 (32.5) 22,340 (31.0) 18,462 (31.6) 37,849 (30.2)
Educationb, n (%)
<7% 24,573 (24.3) 16,103 (22.3) 13,238 (22.6) 27,009 (21.5)
7e12.9% 33,716 (33.4) 23,514 (32.6) 19,002 (32.5) 39,713 (31.7)
13%e20.9% 26,309 (26.0) 19,789 (27.4) 15,705 (26.9) 34,564 (27.6)
21% 16,458 (16.3) 12,802 (17.7) 10,536 (18.0) 24,121 (19.2)
Abbreviations: SD, standard deviation.
a Median residential household income estimated using the 2012 American Community Survey.
b Proportion of adults in patient’s ZIP code who did not complete high school, measured in the 2012 American Community Survey.reduce thenumberofpatients that forgoneededhealth care.Ourdata
suggests, however, that there are still significant disparities in cancer
care betweenMedicaid patients and patients with private insurance.
Direct spending on cancer care in the US doubled between 1990
($63billion) and2010 ($125billion), and spending is estimated to rise
to more than $173 billion by 2020.28 Unfortunately, the benefits of
increased cancer care funding has not been uniformly enjoyed by
many Americans. Our data show that the rates of stage IV CRC have
been increasing continuously since 2008. This is frustratingFig. 1. Yearly trends in the percentage of patients diagnosed at each stage of disease,
among patients with esophageal cancer.considering theavailable andeffective screening tools for thisdisease,
and highlights that further work is needed, including increasing eq-
uity in access to cancer prevention and care. A framework for elimi-
nating CRC disparities was recently proposed, which includes
preventive interventions that combine population-based outreach
with office visit-based strategies.29 Electronic health records systems
with automated monitoring and alerts of screening status are also
currently used and have proven to increase uptake of screening pro-
grams.30 A recent study has shown that education plus tailoredFig. 2. Yearly trends in the percentage of patients diagnosed at each stage of disease,
among patients with colorectal cancer.
Table 3
Adjusted odds between race, residential income, travel distance, and primary insurance type with stage at diagnosis, stratified by esophageal and colorectal cancer.














White REF REF REF REF REF REF
Black 1.06 (0.97, 1.15) 1.25 (1.15, 1.37) 1.04 (0.96, 1.13) 0.94 (0.91, 0.97) 1.06 (1.03, 1.10) 1.34 (1.30, 1.37)
Other 1.20 (1.02, 1.42) 1.44 (1.22, 1.69) 1.11 (0.95, 1.30) 1.03 (0.98, 1.09) 1.14 (1.08, 1.20) 1.05 (1.00, 1.10)
Primary insurance
Private REF REF REF REF REF REF
Medicaid 1.11 (0.99, 1.23) 1.20 (1.08, 1.33) 1.34 (1.21, 1.47) 1.44 (1.37, 1.51) 1.44 (1.37, 1.52) 1.94 (1.86, 2.02)
Medicare 0.78 (0.72, 0.83) 0.78 (0.74, 0.82) 0.77 (0.73, 0.81) 1.06 (1.03, 1.10) 1.03 (1.00, 1.06) 1.11 (1.08, 1.14)
Uninsured 1.12 (0.96, 1.32) 1.53 (1.31, 1.78) 1.99 (1.72, 2.31) 2.05 (1.92, 2.17) 1.90 (1.78, 2.02) 2.33 (2.21, 2.46)
Travel distance
<4 miles REF REF REF REF REF REF
4e7.9 miles 0.98 (0.91, 1.05) 1.00 (0.93, 1.08) 0.92 (0.86, 0.99) 0.97 (0.94, 1.00) 0.98 (0.95, 1.01) 0.99 (0.96, 1.01)
8e17.9 miles 0.94 (0.88, 1.01) 0.99 (0.92, 1.06) 0.83 (0.78, 0.89) 0.97 (0.94, 0.99) 0.98 (0.95, 1.01) 0.99 (0.97, 1.02)
18 miles 0.78 (0.73, 0.83) 0.79 (0.74, 0.84) 0.50 (0.47, 0.53) 0.99 (0.96, 1.02) 1.00 (0.97, 1.03) 1.20 (1.17, 1.23)
Residential income b
<$38,000 REF REF REF REF REF REF
$38,000 - $47,999 0.99 (0.92, 1.07) 1.03 (0.96, 1.12) 1.02 (0.94, 1.09) 0.95 (0.92, 0.98) 0.94 (0.90, 0.97) 0.93 (0.90, 0.96)
$48,000 - $62,999 0.96 (0.88, 1.04) 0.98 (0.90, 1.06) 0.93 (0.86, 1.00) 0.95 (0.92, 0.98) 0.95 (0.91, 0.98) 0.94 (0.91, 0.97)
$63,000 0.94 (0.86, 1.03) 1.03 (0.94, 1.12) 0.91 (0.82, 0.99) 0.97 (0.93, 1.01) 0.97 (0.93, 1.01) 0.97 (0.94, 1.01)
Education c
<7% REF REF REF REF REF REF
7e12.9% 0.99 (0.93, 1.06) 1.02 (0.95, 1.09) 1.05 (0.98, 1.11) 1.07 (1.04, 1.10) 1.06 (1.02, 1.09) 1.05 (1.03, 1.08)
13%e20.9% 0.97 (0.90, 1.05) 1.03 (0.95, 1.11) 1.05 (0.97, 1.13) 1.14 (1.11, 1.18) 1.09 (1.05, 1.13) 1.10 (1.07, 1.13)
21% 0.98 (0.89, 1.08) 1.10 (1.00, 1.21) 1.09 (1.00, 1.19) 1.15 (1.10, 1.19) 1.09 (1.05, 1.14) 1.11 (1.07, 1.15)
Statistically significant results (p < 0.05) are denoted in bold.
a Adjusted for race, primary insurance, travel distance, residential income, education, age, sex, Charlson-Deyo comorbidity score, and year of diagnosis.
b Median residential household income estimated using the 2012 American Community Survey.








White REF REF REF
Black 0.94 (0.91, 0.97) 1.04 (1.00, 1.08) 1.34 (1.30, 1.38)
Other 1.00 (0.95, 1.06) 1.12 (1.05, 1.19) 1.02 (0.97, 1.07)
Primary insurance
Private REF REF REFnavigation (in person or via phone) addressing individual barriers to
screening are the most important components of any educational
program aiming to increase adherence to CRC screening.31
This retrospective study has several limitations. The NCDB is not
population-based registry, but rather identifies patients from 1500
commission-accredited cancer programs, and potentially limits the
generalizabilityofourpatientpopulation. Inaddition, codingerrorsor
different coding practices can occur among the different participant
centers. Education and income are not patient-level measurements,
but rather zip code-level covariates obtained from the 2012American
Community Survey and misclassification in these two disparity var-
iables is possible. Finally, although screening for CRC is recommended
for the general populationwewere not able to determine the rate of
screening adherence in our study period.Medicaid 1.42 (1.34, 1.50) 1.43 (1.35, 1.51) 1.93 (1.85, 2.03)
Medicare 1.07 (1.04, 1.10) 1.03 (1.00, 1.07) 1.12 (1.10, 1.15)
Uninsured 2.11 (1.97, 2.26) 1.93 (1.79, 2.07) 2.56 (2.41, 2.72)
Travel distance
<4 miles REF REF REF
4e7.9 miles 0.96 (0.94, 0.99) 0.98 (0.95, 1.01) 0.98 (0.95, 1.00)
8e17.9 miles 0.96 (0.93, 0.99) 0.98 (0.95, 1.01) 0.98 (0.95, 1.00)
18 miles 0.98 (0.96, 1.01) 1.01 (0.98, 1.04) 1.16 (1.13, 1.19)
Residential income b
<$38,000 REF REF REF
$38,000 - $47,999 0.94 (0.91, 0.98) 0.93 (0.90, 0.97) 0.93 (0.90, 0.96)
$48,000 - $62,999 0.95 (0.91, 0.98) 0.95 (0.91, 0.98) 0.95 (0.92, 0.98)Conclusions
The effect of racial and socioeconomic disparities on stage at
diagnosis are more pronounced in adults with CRC, compared to
esophageal cancer. Additionally, despite recommended screening
guidelines and protocols, the rates of advanced CRC have increased
between2004 and2015. Equity in access to screening and cancer care
should be prioritized to reduce health disparities.$63,000 0.97 (0.93, 1.01) 0.97 (0.92, 1.01) 0.98 (0.95, 1.02)
Education c
<7% REF REF REF
7e12.9% 1.07 (1.03, 1.10) 1.06 (1.03, 1.10) 1.06 (1.04, 1.09)
13%e20.9% 1.14 (1.10, 1.18) 1.10 (1.06, 1.14) 1.12 (1.08, 1.15)
21% 1.14 (1.10, 1.19) 1.09 (1.04, 1.15) 1.13 (1.09, 1.17)
Statistically significant results (p < 0.05) are denoted in bold.
a
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